Drug Trial Radar · NCT06268873
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,554
Actual
Start
Mar 29, 2024
Primary completion
Feb 24, 2028
Study completion Feb 24, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin; and approximately 12-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 12-weeks (approximately), where reassessment of eGFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
Conditions
- Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozinDrug
baxdrostat tablet dapagliflozin tablet
Dapagliflozin in combination with placeboDrug
dapagliflozin tablet placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR over time.Time frame: Baseline - 2 years + 12 weeks
Locations
565 sites in 38 countries. Site status is shown where the registry gives one.
Research Site
Fairhope, Alabama
Research Site
Phoenix, Arizona
Research Site
Surprise, Arizona
Research Site
Tucson, Arizona
Research Site
Searcy, Arkansas
Research Site
Beverly Hills, California
Research Site
Canyon Country, California
Research Site
Fremont, California
Research Site
Fullerton, California
Research Site
Lincoln, California
Research Site
Los Alamitos, California
Research Site
San Francisco, California
Research Site
Stanford, California
Research Site
Tarzana, California
Research Site
Arvada, Colorado
Research Site
Denver, Colorado
Research Site
New Britain, Connecticut
Research Site
Boca Raton, Florida
Research Site
Boynton Beach, Florida
Research Site
Edgewater, Florida
Research Site
Fort Lauderdale, Florida
Research Site
Hialeah, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Jacksonville Beach, Florida
Research Site
Lake City, Florida
Research Site
Lake Worth, Florida
Research Site
Melbourne, Florida
Research Site
Miami, Florida
Research Site
Miami Lakes, Florida
Research Site
New Port Richey, Florida
Research Site
Ocoee, Florida
Research Site
Orlando, Florida
Research Site
Orlando, Florida
Research Site
Port Charlotte, Florida
Research Site
Port Orange, Florida
Research Site
Riverview, Florida
Research Site
Winter Haven, Florida
Research Site
Atlanta, Georgia
Research Site
Conyers, Georgia
Showing 40 of 565 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.